Most of the information on predisposing factors and mortality in status epilepticus (SE) arises from data obtained from patients presenting to the casualty department. However, another population which is frequently seen by consultative neurologists are medically ill patients who develop SE while in hospital. These patients are often notoriously difficult to treat once SE arises. We sought to characterize patients at risk for SE arising when they are hospitalized for other reasons. By doing this, risk factors for developing SE and prognostic indicators might be determined.
INTRODUCTION
Most data on status epilepticus (SE) derive from studies of patients admitted to the hospital in SE or with SE treated in the field. The majority of these cases of SE in adults occur in patients with a known history of epilepsy [1] [2] [3] [4] [5] , in patients with known structural lesions of the central nervous system, usually due to cerebrovascular disease 4 , or in patients with alcohol abuse 6, 7 . In children, infection is the most common underlying precipitating factor 4 . With modern management prognosis for patients has improved. Mortality in adults approximates 10-30% 8, 9 , although the mortality is higher in the elderly 4 , and in patients with subtle SE 10 . Status epilepticus developing in patients already hospitalized for reasons unrelated to epilepsy or prior seizures is most likely due to symptomatic SE, secondary to a variety of medical causes 11 . However, no study has specifically addressed SE developing in patients already in the hospital who had not ini-tially been admitted because of epilepsy or seizure exacerbation. This may represent a distinct subgroup of patients, with unique risk factors and a higher mortality. Our study thus sought to characterize patients who developed in-hospital SE. We describe associated aetiological factors and outcome associated with SE in 41 patients who were initially admitted to the hospital for reasons other than seizures, in whom SE developed while in hospital.
MATERIALS AND METHODS
A retrospective analysis was performed in three urban hospitals in the United States, and the charts of all patients who developed clinical SE over a 1 year period were reviewed. Charts were obtained from medical records following a search under a primary or secondary discharge diagnoses of epilepsy, seizures, SE, and convulsive disorders. Also, we reviewed the EEG and Neurology service consult log books, searching for patients with diagnoses suggesting SE. SE was defined as a seizure lasting greater than 30 minutes or repeated seizures without recovery of normal neurological function between attacks. Information was obtained about concurrent medical conditions, medications, duration, outcome, and EEG findings. Patients were excluded if they (a) arrived at the casualty department in SE, (b) were admitted for an epilepsy-related problem such as video monitoring or drug intoxication, or (c) were less than 1 year old.
RESULTS

Patient characteristics
Forty-one patients with SE were identified and included for study. There were 28 males and 13 females. The age range was between 1 and 91 years with a mean of 60 years and a median of 65 years. Four patients were aged between 1 and 20 years, 22 were aged between 21 and 70 years, and 15 were aged 71 years or older. The mean interval between hospital admission and the development of SE was 26 days. Eight patients (20%) had a history of pre-existing epilepsy before hospital admission. Eleven other patients (27%) had developed an acute symptomatic, sporadic single seizure while in-hospital before the development of SE. Thus a total of 19 patients (47%) had a history of seizures before they developed SE. Of these, six were not on any anticonvulsant medication at the time SE developed, and four had 'sub-therapeutic' serum drug concentrations. Therefore 10 of the 19 patients with a prior history of seizures may have been undertreated at the onset of SE. In most cases, the presence of convulsive vs. non-convulsive SE could not be determined. Underlying conditions (Table 1) Eighteen patients (44%) had active pulmonary disease, 15 (37%) had active cardiac disease, eight (20%) had renal impairment and seven (17%) had hepatic impairment. Twenty-nine patients (71%) had multiple medical problems. A significant metabolic contribution was present in 23 patients (56%). This included hypoxia, sepsis, hepatic encephalopathy, electrolyte imbalance, and organ failure. Diabetes mellitus was present in six patients (15%). Eleven patients (27%) who developed SE while in hospital were taking a theophylline preparation, although only one had a serum theophylline concentration in the 'toxic' range. Two patients developed SE following cardiac surgery, and another two patients had underlying hypertensive encephalopathy.
Focal presentation of SE
Significant focal CNS disturbance was present in 25 patients (61%). Of these, 17 had evidence of cerebrovascular disease (equally divided between recent and remote events), six had recent neurosurgery, and five had a primary or metastatic brain tumour. Many patients had an apparent focal presentation to their SE. When EEG was performed during SE, focal abnormalities were common. However, this was not predictive of a prior or subsequent finding of a focal CNS process. Focal abnormalities on neurological examination or focal EEG abnormalities were found in 18 of 25 of patients (72%) with prior or subsequent focal CNS disease, and in 11 of 16 (69%) without focal CNS disease.
Outcome and mortality
Overall, 25 of the 41 patients died (mortality of 61%). Of these, nine patients died while in SE, and 16 died subsequently in hospital. Five patients were left in a vegetative state or were left totally disabled and dependent. Only eight patients (20%) returned to baseline and left the hospital.
Outcome and duration of status epilepticus
There was little relationship between the duration of SE and mortality in this study population. Of those who were in SE for 2 hours or less (15 patients), the mortality was 57%, in comparison with a mortality of 60% in those (26 patients) who were in SE for longer than 2 hours.
DISCUSSION
Our study describes a group of hospitalized patients who developed SE following admission for a nonepilepsy-related problem. Our findings suggest that the development of in-hospital SE carries a poor prognosis. This appears to be related more to the underlying condition rather than the duration of SE. Many of these patients with in-hospital SE also had evidence of a focal CNS lesion. Many patients had multiple medical and systemic metabolic derangements in addition to focal structural brain disease. The exact immediate cause triggering SE was often unclear and was likely to be multifactorial in some patients. Focal CNS disturbance is often present in hospitalized SE patients, especially cerebrovascular disease. Interestingly, focal abnormalities detected during SE on neurological or EEG examination are as likely to occur in patients without known structural brain disease as in those with documented structural disease. Therefore, such findings should be interpreted clinically with caution. Transient metabolic and other homeostatic disturbance (e.g. hypoglycemia) can cause focal neurological symptoms and signs 12 , perhaps on the basis of occult cerebrovascular disease.
Both recent and remote stroke were associated with SE, and this is in agreement with a large prospective study of SE in which cerebrovascular disease was particularly prevalent in elderly patients 4 , accounting for 61% of all cases of SE in this age group.
Cerebrovascular disease is also a common precipitant of isolated seizures in the elderly general hospital population 13 . However, in medical and surgical intensive care, narcotic drug withdrawal and metabolic abnormalities are the most common predisposing factors for the development of new-onset seizures 14 .
Not surprisingly, metabolic derangement, including organ failure and electrolyte imbalance, and hypoxiaischaemia were also important predisposing factors in our study, being estimated to have a causal relationship to SE in about 56% of patients.
An interesting finding in our study was the association between theophylline use and SE in about a quarter of patients. The rate of theophylline use in similar sick patients who did not develop SE is not known, but would be expected to be less than 25%. Both acute and chronic theophylline toxicity are well known to predispose to seizures, and seizures associated with therapeutic levels have also been reported 15 . In chronic theophylline toxicity, serum levels do not appear to be predictive of seizure risk 16 . It is possible that even theophylline levels in the therapeutic range may predispose to seizures in sick hospitalized patients with multiple metabolic abnormalities and organ failure. In this group of patients theophylline may need to be used with caution and other bronchodilator therapy considered instead when possible. The mechanism by which theophylline lowers the seizure threshold is unclear, but may be due to antagonism of adenosine 17 .
A prior history of epilepsy was less common in our study than in other studies of SE, again emphasizing the importance of the onset of acute illness as a cause of SE in hospitalized patients. Among our 19 patients with a history of prior seizures, up to 10 may have been undertreated at the time SE developed. In patients with organ failure, free levels of anticonvulsant medication should be monitored when possible.
In our study, the high mortality was probably related to the aetiology of underlying medical illness. It is possible that mortality is not just a direct effect of the underlying medical disorders present in these patients, but that, in addition, the development of symptomatic SE in these sick patients contributes further to their poor prognosis. This has also previously been suggested for patients with cerebrovascular disease who develop SE 4 . SE has important adverse effects including increased metabolic demand, hyperpyrexia, and cerebral hypoxia 18 , all of which may overwhelm already impaired homeostatic mechanisms in compromised sick patients in hospital. The high mortality in our study agrees with a small previous analysis of in-hospital SE in a subgroup of more heterogeneous patients who developed SE 2 . In addition, these findings are consistent with the results of a recent large randomized trial of four different standard treatments for convulsive SE in which the 30 day mortality for patients with clinically obvious SE was 27% compared with 65% for those with subtle SE 10 . Patients in the latter group had much higher rates of concomitant serious general medical illnesses 10 , and thus are more like the in-hospital patients of our study.
Prognosis did not appear dependent on the duration of SE in our patients, in contrast to the findings of other studies 2, 3, 19 . However, our retrospective study is limited in drawing firm conclusions about the relationship of SE duration and prognosis, even in this specific population of patients. It is possible that some patients in our series may have gone unrecognized for some hours before diagnosis of SE was made and treatment initiated. On the other hand, the underlying diseases may have been so critical to outcome, that SE duration had little additional impact.
In conclusion, the development of in-hospital SE appears to be associated with a high incidence of focal brain disease and metabolic abnormalities. Theophylline therapy may predispose to the development of SE in hospitalized patients with multiple medical problems. Hospitalized patients with serious comorbid illnesses or central focal lesions with a history of prior seizures may need to be treated with therapeutic anticonvulsant medication. In-hospital SE carries a poor prognosis, probably related to underlying medical problems. These findings indicate that, compared to an outpatient population with SE, this may be a difficult group to treat. Due to the limited retrospective nature of our study, all risk factors could not be adequately assessed. New treatments are needed for patients with SE, especially for those with underlying serious concomitant illness 10 , and new efforts to better prospectively define risk factors and treatment strategies in this population would be useful. Also, since this population's prognosis may differ, prospective treatment protocols may need to stratify patients on this variable, in addition to other previously recognized variables such as seizure duration, which do not seem as critical in this population.
